as 10-28-2025 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $46.86 | AVG Volume (30 days): | 454.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.82 - $42.05 | Next Earning Date: | 10-28-2025 |
| Revenue: | $597,973,000 | Revenue Growth: | 55.68% |
| Revenue Growth (this year): | 53.93% | Revenue Growth (next year): | 25.06% |
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 22 '25 | Sell | $38.83 | 97,390 | $3,781,653.70 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 21 '25 | Sell | $38.77 | 39,331 | $1,524,862.87 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 20 '25 | Sell | $39.07 | 121,248 | $4,717,015.02 | 111,794 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Oct 20 '25 | Sell | $39.02 | 50,490 | $1,962,781.45 | 40,281 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Oct 14 '25 | Sell | $37.82 | 12,368 | $465,843.22 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 29 '25 | Sell | $38.33 | 42,000 | $1,609,860.00 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 15 '25 | Sell | $36.73 | 16,400 | $597,975.80 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 5 '25 | Sell | $35.66 | 13,389 | $477,451.74 | 29,237 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 4 '25 | Sell | $35.52 | 85,271 | $3,028,825.92 | 29,237 | |
| Moat Ross | KNSA | CHIEF CORP. & COMM. OFFICER | Sep 4 '25 | Sell | $35.31 | 3,523 | $124,397.13 | 9,415 |
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
GlobeNewswire
12 days ago
Zacks
13 days ago
Zacks
2 months ago
Zacks
2 months ago
Zacks
2 months ago
MT Newswires
2 months ago
MT Newswires
2 months ago
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.